Hemophagocytic Syndrome: a Rare but Fatal Complication after Liver Transplantation.
Fu Bin-sheng,Yang,Li Hua,Zhang Tong,Chen Gui-hua
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130979
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Hemophagocytic syndrome (HPS) is recognized as a disorder characterized by a variety of symptoms including fever, jaundice, skin rash, lymphadenopathy, and hepatosplenomegaly related to uncontrolled systemic T-cell activation.1 Two forms of HPS have been characterized: primary/familial hemophagocytic lymphohistiocytosis and secondary/reactive HPS. Reactive HPS was first described in 1979 by Risdall et al.2 Although most patients with HPS are immunocompromised, only a small number of patients with HPS have been reported following liver transplantation (LT), suggesting a low level of awareness for this hematological disorder after transplantation. We herein report one patient who underwent LT and in whom HPS subsequently developed. The patient had an aggressive clinical course and fatal outcome. The observation of one case of HPS in a cohort of 741 patients who underwent LT in our center raised the possibility that the case of HPS in these immunocompromised patients might be increasing in the future. Because of this, we reviewed the literature and analyzed the clinical characteristics, diagnosis, and treatment of HPS after LT. The patient was a 45-year-old man who had a 9-year history of chronic hepatitis B virus related mild cirrhosis and was diagnosed with primary carcinoma of the liver in February 2009. On 5 March 2009, he underwent LT after receiving transhepatic arterial chemoembolization (TACE) two weeks before in the Third Affiliated Hospital of Sun Yat-sen University, China. Post-transplantation immunosuppression was maintained with tacrolimus and prednisolone. The early post-operative course was uneventful and liver function tests disclosed the usual pattern from days 0 to 10. Thirty-six days after LT, the patient gradually began to experience high fever, splenomegaly, extensive skin rash, and colonic type diarrhea. Laboratory studies showed pancytopenia (hematocrit, 21%; white blood cell count, 210/mm3; platelet, 49 000/mm3) despite multiple blood transfusions and administration of granulocyte colonystimulating factor (G-CSF). All medications with possible hepatotoxic and bone marrow suppressive effects were discontinued. His serum liver functions were within normal limits. The trough level of tacrolimus, which was administered orally, was 13.0 ng/ml. He was also on prednisolone (0.15 mg·kg-1·d-1). Although his temperature was constantly elevated at 38.5–39°C, bacteriological cultures of blood, urine, stool, and ascetic fluid were negative. No causative agent was identified through his microbiologic culture and serology work (bone marrow, blood, urine, sputum, and feces), and chest X-ray was normal. All other bacterial, fungal, and viral screenings for hepatitis A, B, or C virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human-herpes virus 6 or 7, varicella-zoster virus, parvovirus B19, or adenovirus, performed on blood were negative. On the 40th post-operative day, his white blood cell count decreased to 130/mm3 with 0 neutrophils. The counts were maintained 100–190/ mm3 by several more transfusions, but never returned to the normal level. Hemostatic function also declined with a prothrombin time of 19.0 seconds. A bone marrow examination showed a very low degree of proliferative activity except for a minimally increased content of macrophages. Since the pancytopenia progressed despite multiple blood transfusions and administration of G-CSF, a second bone marrow examination was performed, one week after the first examination. The bone marrow smear revealed many activated macrophages showing phagocytosis, strongly suggestive of HPS (Figure 1A). The diagnosis of HPS was established based on clinical findings, laboratory data, and bone marrow smear examination.Figure 1. A:: Typical hemophagocytosis in bone marrow. Bone marrow smear done on day 47 post-transplantation showed prominent activated macrophages, which ingested red blood cell. Arrow head: activated macrophage, Arrow: ingested red blood cell (Wright-Giemsa, original magnification ×1000). B: Typical image of CT scan indicated intracranial hemorrhage. CT scan done on day 50 post-transplantation showed hemorrhage in the right frontal lobe.Since high ferritin level was associated with HPS, the level was checked once a week after the event occurred. When the HPS occurred, the ferritin level was elevated to 1650 ng/ml (normal range: 22–322 ng/ml). During this period the patient's serum bilirubin levels were increasing, reaching 11.3 mg/dl, although his liver enzymes were totally normal. There was no evidence of biliary obstruction on ultrasonographic examination. There was no familial history of hematological disorder or death of unknown causes. The mean blood level of tacrolimus, which was administered orally, during the 10 days before the diagnosis of HPS was (9.3±3.2) ng/ml (range: 7.0–19.1 ng/ml). The tacrolimus was discontinued and converted to cyclosporine (75 mg twice a day) when the diagnosis of HPS is established. Management with high-dose steroid pulse (started 120 mg twice a day and was gradually tapered to 20 mg) and intravenous immunoglobulin supplementation (25 g twice a day) failed to control his critical condition, which deteriorated rapidly. He died of intracranial hemorrhage (Figure 1B) and multiple organ failure on day 54 after LT. Although the pathogenesis of HPS is not fully understood, this condition may be initiated by activated T cell-mediated immune responses to various conditions including familial disorder, infection, neoplasm, and autoimmune disease. EBV, CMV, and HHV-6 have been associated to HPS in transplant recipients. The presence of viral infections must therefore be ruled out before other causes are investigated. The diagnosis of HPS was established based on clinical findings, laboratory data, and bone marrow biopsy. According to the guidelines,3 our patient fulfilled six criteria: fever, bicytopenia, splenomegaly, hypertriglyceridemia, hyperferritinemia, and hemophagocytosis. Quantitative measurement of interferon (IFN)-gamma, β-2 microglobulin, and soluble interleukin (IL)-2R are useful predictors of diagnosis and prognosis. Although we did not measure serum cytokines in this patient, the transplant setting, and particularly immunosuppressive medications are known to affect serum cytokine profiles. Bone marrow smear, the most sensitive diagnostic test, must be performed as early as possible to establish the diagnosis when HPS is suspected. However, timing of bone marrow examination is also important. Because, in the early stages of the disease, the bone marrow examination often shows only moderate hyperplasia without any typical diagnostic features; hemophagocytosis is usually not evident. Hemophagocytosis is often absent in the first bone marrow examination, and a second examination is sometimes required to establish the diagnosis. That was the case in our patient. Thus we agree with the recommendation for a repeat bone marrow examination, if the clinical findings suggest HPS. Patients with pancytopenia are often encountered in liver transplant recipients with bone marrow suppression. The clinical and laboratory findings are similar between thrombotic microangiopathy (TMA) and HPS. For differential diagnosis, bone marrow biopsy should be performed. The differential diagnosis in the post-transplantation setting should also include T-cell lymphoma or post-transplantation lymphoproliferative disorder (PTLD), and malignant histiocytosis. In addition, graft-versus-host disease (GVHD) is also a serious complication that can occur after LT. Since the mechanisms of onset of GVHD and HPS are alloimmune and autoimmune respectively, identification of a bias toward either anti-host or anti-donor response in patients by mixed lymphocyte reaction enables a definitive diagnosis to be made. Although the specific treatment of HPS for solid organ recipients remains to be defined, treatment of triggering factors using anti-infectious agents and tapering immunosuppressive drugs is of utmost importance, in combination with current supportive treatment, such as administration of G-CSF and intravenous immunoglobulin. Based on a better understanding of the possible role of T lympocytes and macrophages, steroid mini-pulse therapy seemed to have a positive effect on the HPS to suppress the hypercytokinemia. Additionally, treatment with antithymocyte globulin (ATG) or cyclosporine A has been proposed during primary HPS. Calcineurin inhibitor was converted to cyclosporine A, because previous reports showed the superiority of cyclosporine as an immunosuppressant, which was effect for HPS occurring in non-transplantation patients. Conversely, our data show that immunosuppressive drugs such as cyclosporine A, which strongly inhibit T lymphocytes, are not efficient to stop the development of reactive HPS. In refractory cases, anecdotal reports found plasmapheresis, leukocytopheresis, etoposide, and bone marrow or stem cell transplantation to be effective for life-threatening HPS in non-transplantation patients.4 As for bone marrow or stem cell transplantation, we could not find suitable donors during the limited time under the rapidly deteriorating conditions in this case.